Discovery of PHA-739358

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 281-307

  Fancelli, Daniele ^a   Moll, Jürgen ^b  

^a Congenia Srl ^*  (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

PHA 739358 discovery; PHA 739358 profile; Structure of Aurora A in complex with compound 21

Indexed keywords

EID: 84863768282     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch11     Document Type: Chapter

References (59)

1. Bergnes, G., Brejc, K., and Belmont, L. (2005). Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem. 5 (2), 127-145.
2. Berta, D., Felder, E. R., Villa, M., et al. (2002). WO 02/62804.
3. Bischoff, J. R., Anderson, L., Zhu, Y., et al. (1998). A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17 (11), 3052-3065.
4. Böhmer, F. D., Karagyozov, L., Uecker, A., et al. (2003). A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem. 278 (7), 5148-5155.
5. Briassouli, P., Chan, F., Savage, K., et al. (2007). Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 67 (4), 1689-1695.
6. Carpinelli, P., and Moll, J. (2008). Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets. 12 (1), 69-80.
7. Carpinelli, P., Ceruti, R., Giorgini, M. L., et al. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 6 (12 Pt 1), 3158-3168.
8. Cheetham, G. M., Charlton, P. A., Golec, J. M., et al. (2007). Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 251 (2), 323-329.
9. Cohen, R. B., Jones, S. F., von Mehren, M., et al. (2008). Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/ with G-CSF in a 14-day cycle in patients with advanced solid tumors. J Clin Oncol. 26(Suppl), Abst 2520.
10. De Carcer, G., Perez de Castro, I., and Malumbres, M. (2007). Targeting cell cycle kinases for cancer therapy. Curr Med Chem. 14 (9), 969-985.
11. De Jonge, M., Steeghs, N., Verweij, J., et al. (2008). Phase I study of the Aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on days 1, 8, 15 every 4 wks in patients with advanced solid tumors. J Clin Oncol. 26 (Suppl), Abst 3507.
12. Dewar, H., Tanaka, K., Nasmyth, K., et al. (2004). Tension between two kinetochores suffices for their bi-orientation on the mitotic spindle. Nature. 428 (6978), 93-97.
13. Ewart-Toland, A., Dai, Q., Gao, Y. T., et al. (2005). Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis. 26 (8), 1368-1373.
14. Fancelli, D., Pittala, V., and Varasi, M. (2002). WO 02/012242.
15. Fancelli, D., Berta, D., Bindi, S., et al. (2005a). Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 48 (8), 3080-3084.
16. Fancelli, D., Forte, B., Moll, J., et al. (2005b). WO 05/005427.
17. Fancelli, D., Moll, J., Varasi, M., et al. (2006). 1,4,5,6-Tetrahydropyrrolo[3,4-c ]pyrazoles:identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem. 49 (24), 7247-7251.
18. Fu, J., Bian, M., Jiang, Q., et al. (2007). Roles of Aurora kinases in mitosis and tumorigenesis . Mol Cancer Res. 5 (1), 1-10.
19. Fuller, B. G., Lampson, M. A., Foley, E. A., et al. (2008). Midzone activation of Aurora B in anaphase produces an intracellular phosphorylation gradient. Nature. 453 (7198), 1132-1136.
20. Gautschi, O., Heighway, J., Mack, P. C., et al. (2008). Aurora kinases as anticancer drug targets. Clin Cancer Res. 14 (6), 1639-1648.
21. Giles, F. J., Cortes, J., Jones, D., et al. (2007). MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 109 (2), 500-502.
22. Glover, D. M., Leibowitz, M. H., McLean, D. A., et al. (1995). Mutations in Aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 81 (1), 95-105.
23. Gontarewicz, A., Balabanov, S., Keller, G., et al. (2008). Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 111 (8), 4355-4364.
24. Hans, F., and Dimitrov, S. (2001). Histone H3 phosphorylation and cell division. Oncogene. 20 (24), 3021-3027.
25. Harrington, E. A., Bebbington, D., Moore, J., et al. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 10 (3), 262-267.
26. Hirota, T., Kunitoku, N., Sasayama, T., et al. (2003). Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 114 (5), 585-598.
27. Jabbour, E., Cortes, J. E., Ghanem, H., O ' Brien, S., and Kantarjian, H. M. (2008). Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 8 (1), 99-110.
28. Jeffers, M., LaRochelle, W. J., and Lichenstein, H. S. (2002). Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets. 6 (4), 469-482.
29. Jordan, M. A. (2002). Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2 (1), 1-17.
30. Jordan, M. A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4 (4), 253-265.
31. Katayama, H., Brinkley, W. R., and Sen, S. (2003). The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22 (4), 451-464.
32. Katayama, H., Sasai, K., Kawai, H., et al. (2004). Phosphorylation by Aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 36 (1), 55-62.
33. Ke, Y. W., Dou, Z., Zhang, J., and Yao, X. B. (2003). Function and regulation of Aurora/Ipl1p kinase family in cell division. Cell Res. 13 (2), 69-81.
34. Kobayashi, S., Boggon, T. J., Dayaram, T., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352 (8), 786-792.
35. Kodama, Y., Asai, N., Kawai, K., et al. (2005). The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 96 (3), 143-148.
36. Kufer, T. A., Sillje, H. H., Korner, R., et al. (2002). Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 158 (4), 617-623.
37. Liu, Q., Kaneko, S., Yang, L., et al. (2004). Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 279 (50), 52175-52182.
38. Manfredi, M. G., Ecsedy, J. A., Meetze, K. A., et al. (2007). Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA. 104 (10), 4106-4111.
39. Modugno, M., Casale, E., Soncini, C., et al. (2007). Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358. Cancer Res. 67 (17), 7987-7990.
40. Mora-Bermúdez, F., Gerlich, D., and Ellenberg, J. (2007). Maximal chromosome compaction occurs by axial shortening in anaphase and depends on Aurora kinase. Nat Cell Biol. 9 (7), 822-831.
41. Murata-Hori, M., and Wang, Y. L. (2002). The kinase activity of Aurora B is required for kinetochore-microtubule interactions during mitosis. Curr Biol. 12 (11), 894-899.
42. Onwuazor, O. N., Wen, X. Y., Wang, D. Y., et al. (2003). Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 102 (2), 772-773.
43. Pevarello, P., Brasca, M. G., Amici, R., et al. (2004). 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem. 47 (13), 3367-3380.
44. Pugacheva, E. N., and Golemis, E. A. (2006). HEF1-Aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle. 5 (4), 384-391.
45. Sasayama, T., Marumoto, T., Kunitoku, N., et al. (2005). Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells. 10 (7), 627-638.
46. Sharma, P. S., Sharma, R., and Tyagi, R. (2008). Inhibitors of cyclin dependent kinases:useful targets for cancer treatment. Curr Cancer Drug Targets. 8 (1), 53-75.
47. Simeoni, M., Magni, P., Cammia, C., et al. (2004). Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64 (3), 1094-1101.
48. Soncini, C., Carpinelli, P., Gianellini, L., et al. (2006). PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res. 12 (13), 4080-4089.
49. Spengler, D. (2007). Aurora-C-T191D is a hyperactive Aurora-C mutant. Cell Cycle. 6 (14), 1803-1804.
50. Tamborini, E., Pricl, S., Negri, T., et al. (2006). Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene. 25 (45), 6140-6146.
51. Tomlinson, D. C., Baldo, O., Harnden, P., et al. (2007). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 213 (1), 91-98.
52. Tonani, R., Bindi, S., Fancelli, D., et al. (2004a). WO 04/007504.
53. Tonani, R., Bindi, S., Fancelli, D., et al. (2004b). WO 04/013146.
54. Traquandi, G., Brasca, M. G., D'Alessio, R., et al. (2004). WO 04/104007.
55. Vanotti, E., Cervi, G., Pulici, M., et al. (2004). WO 04/071507.
56. Vulpetti, A., and Bosotti, R. (2004). Sequence and structural analysis of kinase ATP pocket residues. Farmaco. 59 (10), 759-765.
57. Wilkinson, R. W., Odedra, R., Heaton, S. P., et al. (2007). AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis . Clin Cancer Res. 13 (12), 3682-3688.
58. Yang, H., Burke, T., Dempsey, J., et al. (2005). Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase. FEBS Lett. 579 (16), 3385-3391.
59. Zhou, H., Kuang, J., Zhong, L., et al. (1998). Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 20 (2), 189-193